Swiss Study on Subarachnoid Hemorrhage
Launched by UNIVERSITY HOSPITAL, GENEVA · Aug 7, 2017
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
The Swiss Study on Subarachnoid Hemorrhage is looking at how patients with a specific type of brain bleed, known as aneurysmal subarachnoid hemorrhage, are treated across Switzerland. This study involves hospitals that have special departments for brain surgery and critical care, allowing researchers to gather information about the care patients receive and their outcomes after treatment. By collecting this data, the study aims to understand the current standards for treating this condition and how well patients do afterward, including their mental health and cognitive abilities.
To participate in this study, a patient must have a confirmed diagnosis of aneurysmal subarachnoid hemorrhage, which is a bleeding caused by a burst brain aneurysm. Unfortunately, patients whose bleeding source cannot be identified or those with other types of bleeding are not eligible. If someone qualifies and decides to take part, they can expect their clinical information to be recorded in a nationwide database, helping improve future care for similar patients. The study is currently recruiting participants of all ages and genders.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • - Patients admitted with a proven diagnosis of aneurysmal subarachnoid hemorrhage.
- Exclusion criteria:
- • - Patients in whom the source of haemorrhage could not be identified (angiogram-negative SAH) or SAH with other causes than cerebral aneurysms.
About University Hospital, Geneva
The University Hospital of Geneva is a leading academic medical center committed to advancing healthcare through innovative research and clinical excellence. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge medical research with high-quality patient care, fostering a collaborative environment that encourages the translation of scientific discoveries into practical treatments. As a prominent sponsor of clinical trials, the University Hospital of Geneva is dedicated to exploring new therapies and improving patient outcomes, while adhering to the highest ethical standards and regulatory compliance. Its robust infrastructure and expert clinical teams ensure the efficient execution of trials across various medical specialties, contributing significantly to the advancement of global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, , Switzerland
Basel, , Switzerland
Aarau, Aargau, Switzerland
Geneva, Ge, Switzerland
St. Gallen, Saint Gallen, Switzerland
Bern, , Switzerland
Lausanne, , Switzerland
Lugano, , Switzerland
Luzern, , Switzerland
Patients applied
Trial Officials
Karl Schaller, MD
Study Director
University Hospital, Geneva
Bawarjan Schatlo, MD
Principal Investigator
University Hospital, Geneva
Martin N Stienen, MD
Principal Investigator
University Hospital, Geneva
Philippe Bijlenga, MD PhD
Principal Investigator
University Hospital, Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials